GlobeNewswire, Inc.

Press release – No. 24 / 2026 Zealand Pharma announces EU approval of ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome The approval marks the first major advancement in short bowel syndrome treatment in Europe in more than a...

EIN Presswire

With 98% of Americans falling short on EPA and DHA, Zinzino’s Test-Based Nutrition offers a simple, measurable way to track omega-3 levels.

GlobeNewswire, Inc.

Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix® was generally well tolerated with a safety...

GlobeNewswire, Inc.

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is positioned...

GlobeNewswire, Inc.

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal...

GlobeNewswire, Inc.

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements...